Abstract

Increasing the resistance of microorganisms to common antibiotics has led to the discovery of new antimicrobial compounds. Antimicrobial peptides are a suitable option to replace existing antibiotics. Capsular synthesizing enzyme peptides with the ACAN antibacterial sequence are a group of bioactive peptides. In this study, the antimicrobial function of the recombinant peptide CpsA-CpsC-L-ACAN with the Streptococcus agalactiae capsule-synthesizing enzyme and an antibacterial anticancer sequence was evaluated against important nosocomial pathogen bacteria, namely Staphylococcus aureus and E. coli. Based on the obtained results, the recombinant fusion peptide CpsA-CpsC-L-ACAN has good antimicrobial performance. This recombinant fusion peptide has stretching properties and its antibacterial effects can compete with common antibiotics.

中文翻译：

---

测定重组CpsA-CpsC-L-ACAN融合肽对大肠杆菌和金黄色葡萄球菌的抗菌作用

摘要

增加微生物对常见抗生素的耐药性导致发现新的抗微生物化合物。抗菌肽是替代现有抗生素的合适选择。具有ACAN抗菌序列的荚膜合成酶肽是一组生物活性肽。在这项研究中，重组肽 CpsA-CpsC-L-ACAN 与无乳链球菌胶囊合成酶和抗菌抗癌序列对重要的院内病原菌，即金黄色葡萄球菌和大肠杆菌的抗菌功能进行了评估。基于获得的结果，重组融合肽CpsA-CpsC-L-ACAN具有良好的抗菌性能。这种重组融合肽具有伸缩性，抗菌效果可与普通抗生素媲美。